Actively Recruiting
Phase 1 Study to Assess Safety and Interaction Effects of JP-1366 with Clopidogrel, Aspirin, Atorvastatin, and Apixaban in Healthy Adults
Led by Onconic Therapeutics Inc. · Updated on 2025-12-04
96
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and the interactions between the investigational drug JP-1366 and four commonly used medications clopidogrel, aspirin, atorvastatin, and apixaban. This phase 1 clinical trial is designed to understand how JP-1366 affects the bodys response and processing of these drugs in healthy volunteers aged 19 to 64 years. The study aims to assess pharmacokinetic and pharmacodynamic interactions to ensure safe combined use. The trial includes four parts, each focusing on JP-1366 combined with one of the other drugs. The designs vary slightly JP-1366 with clopidogrel uses a randomized, open-label, multiple-dosing, crossover design with six sequences and three treatment periods the other combinations use open-label, multiple-dosing, fixed sequence, three-period designs. Participants receive multiple doses of the drug combinations, with careful monitoring of drug levels and effects in the body over time. Participants will undergo several assessments including blood tests to measure drug concentrations and effects on platelet aggregation and anti-factor Xa activity. These measurements occur at specified times, such as up to 48 hours after dosing. Safety is closely monitored throughout the trial. The overall participation period covers multiple dosing days and follow-up assessments to track how JP-1366 interacts with each medication under study.
CONDITIONS
Brief Title
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here